Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 50Breast 50Genitourinary 34Gastrointestinal 23Thoracic 18Sarcoma 13Other solid neoplasm 11CNS 11Tumor-Agnostic 8Head & Neck 5Lymphoid 4Endocrine 4NET 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2Classical hematology 2Dermatologic 1

Conditions

Uveal Melanoma 1

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
olaparib × Dermatologic × 1 year × Clear all
NCT05524935 2026-04-01

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
37 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡